Асосий контентга ўтиш
AkademIndex

Маҳсулотлар

Ишлаб чиқувчилар учун

AkademBaseЭкотизим учун очиқ API
Шарҳ мақола

Epi-Drugs and Epi-miRs: Moving Beyond Current Cancer Therapies

Reza SalariniaAmirhossein SahebkarMostafa PeyvandiHamid Reza MirzaeiDepartment of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. [email protected]Mahmoud Reza JaafariMaryam Matbou RiahiHamed EbrahimnejadJavid Sadri NahandJamshid HadjatiMobina Ostadi AsramiSara FadaeiRasoul SalehiDepartment of Medical Genetics, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. [email protected]Hamed MirzaeiDepartment of Medical Biotechnology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. [email protected]
2016en
ABI

Аннотация

Epigenetic modifications determine phenotypic characteristics in a reversible, stable and genotype-independent manner. Epigenetic modifications mainly encompass CpG island methylation and histone modifications, both being important in the pathogenesis of malignancies. The reversibility of epigenetic phenomenon provides a suitable therapeutic option that is reactivation of epigenetically silenced tumor-suppressor genes. Inhibition of DNA methyltransferase, histone deacetylase and Aurora B kinase, individually or collectively, could feasibly prevent or reverse the impact of epigenetic silencing. MicroRNAs [miRNAs] are an important layer of epigenetic controlling of gene expression, and serve as diagnostic and prognostic biomarkers as well as treatment targets for several types of cancer. miRNAs are involved inepigenetically silencing or activation of genes, tumor suppressor genes and oncogenes, and their modulation opens new horizons for designing novel cancer therapeutic agents.

Ҳали таржима қилинмаган

Идентификаторлар

Иқтибослар ва манбалар

2 та иқтибос0 та фойдаланилган манба